Literature DB >> 10467371

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

H J Haisma1, H M Pinedo, A Rijswijk, I der Meulen-Muileman, B A Sosnowski, W Ying, V W Beusechem, B W Tillman, W R Gerritsen, D T Curiel.   

Abstract

The utility of adenoviral vectors for cancer therapy is limited due to their lack of specificity for tumor cells. In order to target adenovirus to tumor, the natural tropism of the adenovirus should be ablated and replaced by a tumor-specific binding domain. To this end, a neutralizing anti-fiber antibody conjugated to an anti-EpCAM antibody was created that targets the adenovirus to the EpCAM antigen present on tumor cells. The EpCAM antigen was chosen as the target because this antigen is highly expressed on a variety of adenocarcinomas of different origin such as breast, ovary, colon and lung, whereas EpCAM expression is limited in normal tissues. In these studies, the EpCAM-targeted adenovirus was shown to infect specifically cancer cell lines of different origin expressing EpCAM such as ovary, colon and head and neck. Gene transfer was blocked by excess anti-EpCAM antibody and dramatically reduced in EpCAM negative cell lines, thus showing the specificity of the EpCAM-targeted adenovirus. Importantly, infection with targeted adenovirus was independent of CAR, which is the natural receptor for adenovirus binding, since blocking of CAR with recombinant fiber knob did not affect infection with targeted adenovirus. Apart from the cancer cell lines, the efficacy of targeted viral infection was studied in freshly isolated primary human colon cancer cells. As colon cancer predominantly metastasizes to liver, and adenovirus has a high tropism for hepatocytes, we also sought to determine if the EpCAM-targeted adenovirus showed reduced infectivity of human liver cells. The bispecific antibody could successfully mediate gene transfer to primary human colon cancer cells, whereas it almost completely abolished infection of liver cells. This work thus demonstrates that EpCAM-targeted adenoviral vectors can be specifically directed to a wide variety of adenocarcinomas. This approach may prove to be useful for selective gene therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467371     DOI: 10.1038/sj.gt.3300969

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

2.  A strategy for adenovirus vector targeting with a secreted single chain antibody.

Authors:  Joel N Glasgow; Galina Mikheeva; Victor Krasnykh; David T Curiel
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 3.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

4.  Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter.

Authors:  C Ebbinghaus; A Al-Jaibaji; E Operschall; A Schöffel; I Peter; U F Greber; S Hemmi
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.

Authors:  I Dmitriev; E Kashentseva; B E Rogers; V Krasnykh; D T Curiel
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

Authors:  Victor W van Beusechem; Jacques Grill; D C Jeroen Mastenbroek; Thomas J Wickham; Peter W Roelvink; Hidde J Haisma; Martine L M Lamfers; Clemens M F Dirven; Herbert M Pinedo; Winald R Gerritsen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene.

Authors:  Li-Zong Shen; Wen-Xi Wu; De-Hua Xu; Zhong-Cheng Zheng; Xin-Yuan Liu; Qiang Ding; Yi-Bing Hua; Kun Yao
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

8.  A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

Authors:  John Nemunaitis; Alex W Tong; Michael Nemunaitis; Neil Senzer; Anagha P Phadke; Cynthia Bedell; Ned Adams; Yu-An Zhang; Phillip B Maples; Salina Chen; Beena Pappen; James Burke; Daiju Ichimaru; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

9.  Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Authors:  Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.